IL6 and benign prostatic hyperplasia: Compounds 1 and 2 were shown to potently inhibit the production of cytokines IL-6 and 8, which are autocrine growth factors that play a key role in inducing the development of hyperplasia of the prostate in BPH patients and in prostate cancer cells (Figure 2 and Figure 3) [17,18].